Cardiac Amyloidosis: On the Road
Join us for a Cardiac Amyloidosis symposium in your region.
Cardiac Amyloidosis: Virtual On the Road in Houston
Title: Cardiac Amyloidosis: From Missed and Undiagnosed, to Common and Treatable
Saturday, Oct. 24
8:30 am to Noon (CDT)
Program Director: Mouaz Al-Mallah, MD, FASNCSaturday, Oct. 24
8:30 am to Noon (CDT)
Fee: Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™ or 3.25* ARRT Category A CE credits
*Credits subject to change
|
---|
This program is jointly sponsored by the American Society of Nuclear Cardiology and Houston Methodist.

Cardiac Amyloidosis: Virtual On the Road in South Florida
Title: South Florida Cardiac Amyloid Symposium
Wake up and Look Around
Towards Early Recognition, Diagnosis and Treatment of Cardiac Amyloidosis
Saturday, Oct. 31
8:00 am to Noon (EDT)
Program Director: David Wolinsky, MD, MASNC
Fee: Free for members, $75 for non-members, Join ASNC and Save
Credits: Earn 3.25* AMA PRA Category 1 Credits™ or 3.25* ARRT Category A CE credits
*Credits subject to change
Agenda | ||
Eastern Time | Title | Speaker |
8:00 am | Welcome, Introduction and Knowledge Questions | David Wolinsky, MD |
8:05 am | Overview of Amyloidosis | Frederick Ruberg, MD |
8:40 am | Diagnosis of Cardiac Amyloid in 2020: Guideline Recommendations | Prem Soman, MD, PhD |
9:15 am | Management Strategies | David Wolinsky, MD |
9:50 am | Panel Discussion | |
10:15 am - 10:30 am | Break | |
10:30 am - 11:30 am |
Case Based Learning
|
Abdullah Sarkar, MD – Presenter David Wolinsky, MD – Discussant Syed Bukhari, MD Prem Soman MD, PhD Diana Miranda, MD – Presenter Viviana Navas, MD – Discussant |
11:30 am - Noon | What the Future Holds and Closing Remarks | David Wolinsky, MD |
Register for upcoming webinars and view our extensive archives and portfolio of online education available for CME/CE credits.
The Cardiac Amyloidosis: On the Road programs will:
- Address the knowledge, competence and performance gaps in disease epidemiology, pathophysiology, diagnosis and treatments for ATTR-CM.
- Improve diagnosis across all patient populations, timely referral to amyloid experts, and knowledge of treatment options with the goal of improving outcomes of patients with ATTR-CM.
- Enhance the understanding of the overlap of cardiac amyloidosis with other conditions leading to a misdiagnosis or delayed diagnosis.
- Focus on the diagnostic algorithm, including the appropriate use of Tc-99m PYP, and the importance of image interpretation alongside other clinical findings.
- Discuss the central role of Tc-99m PYP imaging and the protocols for acquisition, processing and interpretation to ensure understanding of the procedure and the data it provides.
- Describe amyloidosis, including specific types, cardiac features and disease burden.
- Identify barriers to identification and diagnosis of patients suspected of ATTR.
- Recognize patients at risk for hereditary ATTR (hATTR) and wild-type ATTR (wtATTR).
- Summarize the diagnostic evaluation for cardiac amyloidosis including the differential diagnosis.
- Provide details of Tc-99m PYP including imaging protocol, semi-quantitative and quantitative scoring, interpretation including identifying false positive and false negative studies, and components of an appropriate report.
- Demonstrate understanding of current treatments for patients with ATTR-CM.
If you have any questions about registration, please contact info@asnc.org
These programs are supported by educational grants from Pfizer.